TY - JOUR
T1 - Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid β-protein precursor
AU - Van Nostrand, William E.
AU - Wagner, Steven L.
AU - Suzuki, Michiyasu
AU - Choi, Ben H.
AU - Farrow, Jeffrey S.
AU - Geddes, James W.
AU - Cotman, Carl W.
AU - Cunningham, Dennis D.
PY - 1989
Y1 - 1989
N2 - PROTEASE nexin-II (PN-II) is a protease inhibitor that forms SDS-resistant inhibitory complexes with the epidermal growth factor (EGF)-binding protein, the γ-subunit of nerve growth factor, and trypsin. The properties of PN-II indicate that it has a role in the regulation of certain proteases in the extracellular environment. Here we describe more of the amino-acid sequence of PN-II and its identity to the deduced sequence of the amyloid β-protein precursor (APP). Amyloid β-protein is present in neuritic plaques and cerebrovascular deposits in individuals with Alzheimer's disease and Down's syndrome. A monoclonal antibody against PN-II (designated mAbP2-1) recognized PN-II in immunoblots of serum-free culture medium from human glioblastoma cells and neuroblastoma cells, as well as in homogenates of normal and Alzheimer's disease brains. In addition, mAbP2-1 stained neuritic plaques in Alzheimer's disease brain. PN-II was a potent inhibitor of chymotrypsin with an inhibition constant Ki of 6 × 10-10 M. Together, these data demonstrate that PN-II and APP are probably the same protein. The regulation of extracellular proteolysis by PN-II and the deposition of at least parts of the molecule in senile plaques is consistent with previous reports that implicate altered proteolysis in the pathogenesis of Alzheimer's disease.
AB - PROTEASE nexin-II (PN-II) is a protease inhibitor that forms SDS-resistant inhibitory complexes with the epidermal growth factor (EGF)-binding protein, the γ-subunit of nerve growth factor, and trypsin. The properties of PN-II indicate that it has a role in the regulation of certain proteases in the extracellular environment. Here we describe more of the amino-acid sequence of PN-II and its identity to the deduced sequence of the amyloid β-protein precursor (APP). Amyloid β-protein is present in neuritic plaques and cerebrovascular deposits in individuals with Alzheimer's disease and Down's syndrome. A monoclonal antibody against PN-II (designated mAbP2-1) recognized PN-II in immunoblots of serum-free culture medium from human glioblastoma cells and neuroblastoma cells, as well as in homogenates of normal and Alzheimer's disease brains. In addition, mAbP2-1 stained neuritic plaques in Alzheimer's disease brain. PN-II was a potent inhibitor of chymotrypsin with an inhibition constant Ki of 6 × 10-10 M. Together, these data demonstrate that PN-II and APP are probably the same protein. The regulation of extracellular proteolysis by PN-II and the deposition of at least parts of the molecule in senile plaques is consistent with previous reports that implicate altered proteolysis in the pathogenesis of Alzheimer's disease.
UR - http://www.scopus.com/inward/record.url?scp=0024463491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024463491&partnerID=8YFLogxK
U2 - 10.1038/341546a0
DO - 10.1038/341546a0
M3 - Article
C2 - 2507928
AN - SCOPUS:0024463491
SN - 0028-0836
VL - 341
SP - 546
EP - 549
JO - Nature
JF - Nature
IS - 6242
ER -